Influence of the transjugular intrahepatic portosystemic shunt (TIPS) in cirrhotic patients on sarcopenia

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00024507

Enrollment

100

Registered

2023-06-13

Start date

2023-06-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Muscle wasting and atrophy, not elsewhere classified, multiple sites M62.59 K74.6

Interventions

Group 1: Retrospective study of sarcopenia and osteoporosis in cirrhotic patients

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: - Patients with liver cirrhosis and indication for TIPS placement - Age = 18 years and < 85 years

Exclusion criteria

Exclusion criteria: - Non-cirrhotic indications for TIPS placement Non-cirrhotic portal vein thrombosis Budd-Chiari Syndrome Nodular regenerative hyperplasia - Age < 18 years and = 85 years - Inability of the patient to consent - Frustrated TIPS system - Hepatocellular carcinoma (HCC)

Design outcomes

Primary

Measure	Time frame
Change in sarcopenia in patients with advanced liver cirrhosis 12 months after TIPS placement	—

Secondary

Measure	Time frame
- Change in sarcopenia in patients with advanced liver cirrhosis 6 months after TIPS placement - To determine the prevalence of osteoporosis in patients with advanced liver cirrhosis presenting for the TIPS facility - Change in osteoporosis in patients with advanced liver cirrhosis and initial diagnosis of osteoporosis at the time of TIPS placement 12 months after TIPS placement	—

Countries

Germany

Contacts

Public ContactMichael Schultheiß

Universitätsklinikum Freiburg

michael.schultheiss@uniklinik-freiburg.de0761-270-34010

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026